CDK-IN-6

• CAT Number: I045035
• CAS Number: 779353-02-5
• Molecular Formula: C21H28N6O
• Molecular Weight: 380.49
• Purity: ≥95%
• Synonyms: 2-[(2S)-1-[3-ethyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
• InChI: InChI=1S/C21H28N6O/c1-2-17-15-24-27-19(23-14-16-6-5-9-22-13-16)12-20(25-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12-13,15,18,23,28H,2-4,7-8,10-11,14H2,1H3/t18-/m0/s1
• InChIKey: FWKFUJKFJMIJDX-SFHVURJKSA-N
• SMILES: CCC1=C2N=C(C=C(N2N=C1)NCC3=CN=CC=C3)N4CCCCC4CCO

CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities[1].
Individual CDK’s, such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8 and the like, perform distinct roles in cell cycle progression and can be classified as either G1, S, or G2M phase enzymes. Uncontrolled proliferation is a hallmark of cancer cells, and misregulation of CDK function occurs with high frequency in many important solid tumors[1].

Reference

[1]. Timothy Guzi, et al. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. US20040209878A1.